IMNN - imunon.com Future Price to Earnings

Official company branding of imunon.com (IMNN)

Imunon, Inc. (IMNN) is pursuing expansion by scaling its IMNN-001 DNA therapy to combat oncology. Management's efforts to treat ovarian cancer are supported by the company's forward P/E, where the value 0.00 reflects the metric's balance. The dynamics of this indicator link the strategy to real market expectations, highlighting the potential of innovative products currently in the clinical trial phase.

Price to Future Earnings Ratio: Imunon (IMNN) for 04/28/2023 - 11/14/2026

Analytical breakdowns and data insights for company imunon.com (IMNN)

- stock value and consensus price forecast:
Price Chart Celsion Corporation|IMNN - Broker Consensus Forecast
- market capitalization statistics:
Market Value Imunon Inc|IMNN - Total Enterprise Value
- balance sheet equity data:
Net Assets per Single Share Imunon|IMNN - Accounting Capitalization|Market Cap to Net Assets Ratio imunon.com|IMNN - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital Imunon, Inc.|IMNN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Celsion Corporation|IMNN - Company Aggregate Debt|Debts to Book Capitalization Imunon|IMNN - Company Long-Term Liabilities|Company Current Liabilities Imunon|Quick Ratio imunon.com
- company profitability and valuation multiples indicators:
IMNN - Net Financial Result|Expected Profit Imunon, Inc.|IMNN - Price to Earnings Ratio|Future Price to Earnings Celsion Corporation|IMNN - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Imunon, Inc.|IMNN - Operating profit before amortization|Net earnings per share (EPS TTM) Imunon|IMNN - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months imunon.com|IMNN - Earnings per share growth this year|Earnings growth forecast for next year Imunon, Inc.
- sales revenue and business income indicators:
IMNN - Revenue and Sales Volume|Projected Sales Volume Celsion Corporation|IMNN - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Imunon
Summary company analytics:Imunon, Inc.
Brand item of Imunon, Inc.

Imunon, Inc. (IMNN) high clinical trial expenditures and the protection of intellectual property via the Plasmids platform create a significant barrier to entry for competitors. The ratio of current market capitalization to projected earnings per share allows for a valuation of future revenues, while the company's forward P/E dynamics help investors determine the premium paid for potential technological monopoly in oncology.

Competitors of Imunon, Inc.

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|editasmedicine.com - Projected Price to Earnings|Market Cap to Projected Earnings silence-therapeutics.com (SLN)|PRQR: Projected Price to Earnings|Projected Price to Earnings Ratio codexis.com|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Biotechnology Inc (NAUT)|Projected Price to Earnings MGX|DTIL (Precision BioSciences) - Market Cap to Future Earnings Ratio|Future Price to Earnings Generation Bio Corp (GBIO)|Boundless Bio - Price to Future Earnings Ratio|Future Price to Earnings Exicure, Inc. XCUR|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple